InterVenn Biosciences Announces the Publication of Early Detection of Advanced Adenoma and Colorectal Cancer in Gastroenterology

Global Leadership Team

Joshua Stahl, MBA

Chief Executive Officer

Joshua has a proven track record of building successful diagnostics companies. In 2013 he started ArcherDX, a leading genomics analysis company developing industry-leading products and services for therapy optimization and cancer monitoring. Throughout his tenure, Joshua held leadership roles with increasing responsibility before becoming Chief Scientific Officer and Chief Operating Officer. He helped build ArcherDX into a leading global diagnostic organization, which was the first to have a Next Generation Sequencing (NGS)-based liquid biopsy companion diagnostic approved by the Pharmaceuticals and Medical Devices Agency. In 2020, ArcherDX was acquired by Invitae Corporation where Joshua served as President of Oncology following the acquisition.

Brian Hogan, MBA

Chief Financial Officer

Brian brings over 20 years of finance and leadership experience in public and private companies to InterVenn. Prior to joining InterVenn, Brian was the CFO at Clear Labs. His previous roles also included: SVP, Global Finance and Accounting at Portola; CFO at Adicet Bio; and VP, Finance at Genomic Health. He earned a bachelor’s degree in Business Administration with a concentration in Finance from California State University, Sacramento, and an MBA from Saint Mary’s College of California.

Daan Hommes, M.D., Ph.D.

Chief Medical Officer

Daan is a trained internist / gastroenterologist with over 25 years of clinical practice. He served various roles including Department Chair and Professor of Gastroenterology and Hepatology at Leiden University Medical Center; Professor of Medicine at University of California Los Angeles (UCLA); President of the European Crohn’s and Colitis Organization (ECCO); Professor of Health Innovation and Applied Artificial Intelligence at the University of Leiden; and Founder and CEO of DEARhealth, a UCLA spin-off company offering AI-powered Care Pathways.

Daan completed his Ph.D. in biomarkers and experimental treatments in Inflammatory Bowel Diseases (IBD) and, having lectured around the world and authored over 280 peer-reviewed papers, he offers InterVenn deep scientific and clinical expertise in host immune responses, malignant transformation processes and biomarker development.

Dan Serie, M.S.

Chief Data Officer

Dan is the Chief Data Officer at InterVenn, with over 15 years of experience mining the genome and proteome for biological and clinical insights. After joining in late 2017, his team was responsible for training, deploying, and publishing the world's first neural network for mass spectrometry peak selection and integration.

Prior to starting at InterVenn, Dan led analytical efforts for dozens of scientific publications in cancer, neurodegenerative disease, and cardiovascular health at the Mayo Clinic. He holds a Bachelor of Science degree in Mathematics from the University of Minnesota and a Master's in Applied Statistics from Penn State. His team continues development on advanced machine learning techniques for detecting, quantifying, and utilizing glycoproteins, in service of the ultimate goal: moving these novel biomarkers into clinical practice and improving patient outcomes.

Stephana Patton, Ph.D., J.D.

Chief Legal Officer

Stephana brings 20 years of experience creating portfolio value at publicly-traded biotechnology and pharmaceutical companies. She joined us in April 2021. She was formerly the General Counsel, Corporate Secretary, and Chief Compliance Officer of Eiger BioPharmaceuticals, Inc., a commercial stage biopharmaceutical company focused on developing therapies for rare and ultra-rare diseases. Prior to Eiger, she was the General Counsel, Corporate Secretary, and Chief Compliance Officer of BioTime, Inc., a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases.

Prior to BioTime, she was the General Counsel and Commercial Compliance Officer at BioDelivery Sciences (BDSI), a publicly traded specialty pharmaceutical company. Before BDSI, she held various senior management positions, including leading Intellectual Property (IP) and Licensing at Salix Pharmaceuticals, a global pharmaceutical company that was acquired for $11.2 billion in 2015. Prior to joining Salix, Dr. Patton was in private practice at a large international law firm known for its IP and corporate securities practices. Her practice focused on counseling clients on IP-related matters as well as licensing transactions for biotechnology and pharmaceutical companies at varying stages of product development. Dr. Patton earned a J.D. from the Boston University School of Law, and a Ph.D. in Biochemistry, Cell, and Developmental Biology from Emory University.

Business Development

Kim MacMartin-Moglia, MBA

Vice President of Business Development

Kim MacMartin-Moglia is the Vice President of Business Development at InterVenn, with over 25 years of experience in the medical diagnostics industry. During her tenure at InterVenn, Ms. MacMartin-Moglia has developed relationships with partner companies to enable the discovery of novel glycoproteomic biomarker signatures utilized for early diagnosis, disease prognosis and therapeutic response. In addition, she has developed a team of business development professionals to support the company's rapid growth and evolving business development needs. Prior to InterVenn, Kim previously held the position as the Director of Business Development at Inova Diagnostics/Werfen, an autoimmune focused IVD company and as the Director of Business Development at Prometheus Laboratories, a specialty CLIA reference laboratory focused on Gastroenterology/Oncology. She started her career at Quest Diagnostics working in the molecular genetics laboratory and after receiving her MBA, went on to work in sales and marketing roles in positions of increasing responsibility at Quest. She received her B.A. in Biochemistry and Cell Biology from UCSD and her MBA with an emphasis on Marketing and Finance from the University of San Diego.

InterVenn Co-Founders

Aldo Carrascoso, MBA

InterVenn Co-Founder;
Co-Founder, Veem and Jukin Media

Carolyn Bertozzi, Ph.D.

InterVenn Co-Founder; Nobel Laureate; Professor, Stanford University; Member, National Academies of Sciences, Medicine, and Inventors

Carlito Lebrilla, Ph.D.

InterVenn Co-Founder; Distinguished Professor, UC Davis; Fellow, American Academy for the Advancement of Science

Scientific Advisors

Carolyn Bertozzi, Ph.D.

InterVenn Co-Founder; Nobel Laureate; Professor, Stanford University; Member, National Academies of Sciences, Medicine, and Inventors

Carlito Lebrilla, Ph.D.

InterVenn Co-Founder; Professor, UC Davis; Fellow, American Academy for the Advancement of Science

Heinz Läubli, M.D., Ph.D.

Professor, University of Basel

James Allison, Ph.D.

Regental Professor, MD Anderson, Nobel Laureate

Padmanee Sharma, M.D., Ph.D.

Professor, MD Anderson

Arnold Levine, Ph.D.

Professor, Institute of Advanced Study; Member, National Academies of Sciences and Medicine

Medical Advisors

Samir Gupta, MD

University of California, San Diego; San Diego Veterans Affairs

Dr. Gupta is a Professor at the University of California San Diego, within the Division of Gastroenterology. He is a board-certified gastroenterologist with specific expertise in colorectal cancer screening and prevention as well as the management of patients with hereditary colorectal cancer syndromes. His research focuses on reducing the burden of gastrointestinal cancers, including colorectal cancer, across all populations. He has led multiple large-scale comparative effectiveness randomized trials of strategies to boost colorectal cancer screening rates among the underserved, as well as numerous observational studies of the clinical and molecular epidemiology of digestive system cancers and neoplasia, including colorectal, hepatocellular, and pancreatic cancer. Additionally, Dr. Gupta serves as Vice Chair of the National Comprehensive Cancer Network guideline committees for genetic/high risk familial assessment and screening for colorectal cancer and was a prior member of the US Multi-society Task Force on Colorectal Cancer.

Heiko Pohl, MD

Dartmouth Geisel School of Medicine, VA Medical Center

Dr. Pohl is a Professor of Medicine at the VA Medical Center, White River Junction and Dartmouth Geisel School of Medicine. He is a board-certified gastroenterologist who specializes in colorectal cancer screening and developing best practices for colonoscopy and polypectomy. Dr. Pohl has led multiple randomized trials related to the safety of endoscopy resection of large colorectal polyps.

Aasma Shaukat, MD, MPH

NYU Grossman School of Medicine

Dr. Shaukat is a Professor of Medicine at the Departments of Medicine and Population Health at the NYU Grossman School of Medicine. There she serves as the Director of Outcomes Research within the Division of Gastroenterology and Hepatology as well as Co-Director for the Translational Research Education and Careers. She is a board-certified gastroenterologist who specializes in colon cancer screening and colonoscopy as well as the identification of colon polyps and management of patients with lynch syndrome. Her research focuses on the study of colorectal cancer risk factors, screening modalities, long-term outcomes, and quality indicators for colonoscopy. She has a particular interest in minimizing barriers and improve screening for colorectal cancer in underserved communities. She recently served as first author on the newly updated ACG Clinical Guidelines: Colorectal Cancer Screening 2021 published in The American Journal of Gastroenterology. Dr. Shaukat’s research has received funding from the NIH, Department of Veterans Affairs, American College of Gastroenterology, and the American Society for Gastrointestinal Endoscopy.

Evelien Dekker, MD, PhD

Amsterdam University Medical Centers

Dr. Dekker is a Professor of Gastroenterology and Hepatology at the Amsterdam University Medical Centers. She specializes in gastrointestinal oncology and the screening and diagnosis of colorectal cancer. Her research interests include population screening and surveillance for colorectal cancer, quality of colonoscopy and advanced colonoscopic imaging techniques, treatment of colorectal polyps and cancer, and hereditary polyposis syndromes and colorectal cancer. She has published hundreds of articles in peer-reviewed journals, lead multiple clinical trials and studies, and is the global head of the World Endoscopy Organization (WEO) CRC screening committee.

John Nik Ding, MBBS, FRACP, PhD

St. Vincent’s Hospital

Dr. Ding is a Melbourne-based gastroenterologist and Associate Professor at St. Vincent’s Hospital where he is the lead gastroenterologist for the National Bowel Cancer Program. His areas of expertise include bowel cancer screening, irritable bowel disease, and gastro-esophageal reflux disease. He is a member of both the Human Research Ethics Committee (AUS) and the European Crohn’s and Colitis Organization. He is also the founding member of the Young Australian Crohn’s and Colitis Network. His research has been supported through the National Health and Medical Research Council (NHMRC) as well as the European Crohn’s and Colitis Organization. In addition, He is co-founder and director of a medical healthcare company, that is aimed at improving patient care with bowel preparation instructions for colonoscopy.

Get in touch